Velcade Shows Edge In Phase III Multiple Myeloma Trial; Fails In Colorectal
This article was originally published in Pharmaceutical Approvals Monthly
Millennium plans to submit its Phase III Velcade (bortezomib) confirmatory trial in multiple myeloma in the second half of 2004.
You may also be interested in...
Millennium’s Velcade captured 50% to 60% of the third-line multiple myeloma market in the second quarter, the firm reported July 22.
Approval of Millennium’s Velcade in less than four months reflects FDA’s internal goal to approve the multiple myeloma agent before the full six months allotted for the priority review.
Peripheral neuropathy associated with Millennium’s Velcade appears to be reversible in most cases, according to an analysis presented at the American Society of Hematology annual meeting Dec. 9.